Deterioration in renal function associated with fibrate therapy.
about
Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease?Post-transplant dyslipidemia: Mechanisms, diagnosis and managementReversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants.An Increase in Serum Creatinine after Initiation of Fenofibrate in an HIV-Infected Individual: A Case Report and Review of the Literature.A case of membranous glomerulonephritis presenting as pulmonary embolism and acute hyperlipidaemiaThe ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitusCanadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease.Safety and efficacy evaluation of Ayurvedic treatment (Arjuna powder and Arogyavardhini Vati) in dyslipidemia patients: A pilot prospective cohort clinical study.The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice.Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.The hypolipidemic activity of Ayurvedic medicine, Arogyavardhini vati in Triton WR-1339-induced hyperlipidemic rats: A comparison with fenofibrate.Minireview: Won't get fooled again: the nonmetabolic roles of peroxisome proliferator-activated receptors (PPARs) in the heart.Effect of Fenofibrate Medication on Renal Function.
P2860
Q24678615-5FAC3BA4-49BE-49DD-844C-6EB874574B0BQ28076119-86EC765F-16E0-4EE9-ADA3-802B7B5729FBQ30419512-7EC94340-1BBA-4A09-BC77-A3B078F53120Q35569823-CCF44107-FF87-401D-8EA4-9DB7FB196866Q35586249-AC5F34B0-2EB8-41C8-815D-2DED280D2D1BQ35871965-BAAAFD80-689F-4DB6-B1AA-F6D36B9C47E1Q36593266-60B83BBC-BDF9-4241-8F8A-B6A1AE99CE24Q36726951-8C4A82D6-975C-461A-98BA-473B5FE4B3F7Q37079828-0E433068-F0F5-4B49-8721-EA1F3253F7D6Q37254899-C2337C1F-596B-44FA-8B28-0C1D06BAF721Q37290138-C65CEE13-7902-408D-B579-C88044BCF44FQ37656896-5EB0D899-5CFD-4BBD-A9C3-E5EFE3EAB11AQ41223740-09AE5A60-6F32-4197-A5BD-59F790793ADB
P2860
Deterioration in renal function associated with fibrate therapy.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Deterioration in renal function associated with fibrate therapy.
@ast
Deterioration in renal function associated with fibrate therapy.
@en
type
label
Deterioration in renal function associated with fibrate therapy.
@ast
Deterioration in renal function associated with fibrate therapy.
@en
prefLabel
Deterioration in renal function associated with fibrate therapy.
@ast
Deterioration in renal function associated with fibrate therapy.
@en
P2093
P1433
P1476
Deterioration in renal function associated with fibrate therapy
@en
P2093
P577
2001-01-01T00:00:00Z